476060 - Onconic Therapeutics, Inc.

476060 Summary

Biopharma

Stock Price & Overview

₩16,440 -670 (-3.92%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩16,440 ≈ US$12 · Market cap ₩0.7tn (≈ $533m)

476060 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Revenue	53.4	14.8	21.1	0.1
Operating Income	12.6	-4.8	2.2	-14.8
Finance Income	1.4	0.9	0.9	1.4
Finance Costs	0.0	8.1	2.5	1.1
Pretax Income	13.7	-9.9	0.7	-14.4
Income Tax Expense	-2.1	-1.8	-1.0	0.0
Net Income	15.8	-8.1	1.7	-14.4
Total Comprehensive Income	15.7	-8.1	1.7	-14.4

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Total Assets	75.7	60.9	37.5	30.9
Current Assets	63.8	52.1	30.8	28.2
Cash & Cash Equivalents	47.0	43.0	30.1	27.3
Trade Receivables	10.7	7.6	0.4	0.8
Non-current Assets	11.9	8.8	6.8	2.7
Property, Plant & Equipment	2.9	3.0	3.2	2.6
Intangible Assets	0.0	0.0	0.0	0.0
Total Liabilities	3.7	4.9	57.2	52.8
Current Liabilities	3.6	4.8	57.0	26.6
Non-current Liabilities	0.0	0.1	0.2	26.3
Total Equity	72.0	56.0	-19.7	-21.9
Share Capital	22.2	5.4	2.9	2.9
Retained Earnings	26.7	-39.1	-31.0	-32.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022
Cash from Operating Activities	11.4	-7.8	4.1	-15.0
Cash from Investing Activities	-6.2	-0.1	-1.0	-2.4
Purchase of Property, Plant & Equipment	0.3	0.1	1.2	2.6
Cash from Financing Activities	-0.5	19.6	-0.2	25.9
Net Change in Cash	4.7	11.7	3.0	8.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Total Revenue	24.4	23.0	15.6	19.2	9.4	9.2	—
Operating Income	2.8	4.6	1.6	8.3	1.1	1.6	—
Finance Income	0.4	0.4	0.4	0.3	0.4	0.3	—
Finance Costs	0.0	0.0	0.0	0.0	0.0	0.0	—
Pretax Income	3.8	6.4	2.6	9.4	-0.2	1.9	—
Income Tax Expense	0.0	0.0	-2.1	0.0	0.0	0.0	—
Net Income	3.8	6.4	4.7	9.4	-0.2	1.9	—
Total Comprehensive Income	3.7	6.3	4.6	9.4	-0.2	1.9	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Total Assets	93.0	87.6	75.7	73.9	63.6	62.6	60.9
Current Assets	81.0	75.8	63.8	65.4	55.1	53.9	52.1
Cash & Cash Equivalents	58.2	51.8	47.0	46.6	45.2	44.5	43.0
Trade Receivables	18.0	18.1	10.7	9.1	7.9	7.9	7.6
Non-current Assets	12.0	11.8	11.9	8.5	8.6	8.7	8.8
Property, Plant & Equipment	2.9	2.9	2.9	2.9	3.0	2.9	3.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	7.2	8.1	3.7	5.0	4.6	4.2	4.9
Current Liabilities	7.1	8.0	3.6	5.0	4.5	4.1	4.8
Non-current Liabilities	0.1	0.1	0.0	0.0	0.1	0.1	0.1
Total Equity	85.8	79.5	72.0	68.9	59.0	58.4	56.0
Share Capital	22.7	22.4	22.2	5.6	5.5	5.4	5.4
Retained Earnings	36.9	33.1	26.7	22.0	12.6	12.8	-39.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4
Cash from Operating Activities	3.7	3.4	1.9	7.8	0.5	1.2	—
Cash from Investing Activities	0.9	-0.0	1.0	-7.0	-0.2	0.0	—
Purchase of Property, Plant & Equipment	0.1	0.0	0.1	0.0	0.2	0.0	—
Cash from Financing Activities	1.4	1.0	-1.6	0.3	0.6	0.2	—
Net Change in Cash	5.9	4.4	1.2	1.1	0.9	1.4	—

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 4 fiscal years and 7 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

476060 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	53.4	+259.8%	+725.2%	—	—
Operating income	12.6	—	—	—	—
Net income	15.8	—	—	—	—
EPS	₩348	—	—	—	—
Operating cash flow	11.4	—	—	—	—
Shareholders' equity	72.0	+28.6%	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

476060 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022
Operating margin	23.6%	-32.3%	10.6%	-15,618.5%
Net margin	29.6%	-54.5%	8.0%	-15,191.5%
Return on equity	24.7%	-44.6%	—	—
Return on assets	23.1%	-16.4%	4.9%	-46.7%
Operating cash flow / revenue	21.3%	-52.8%	19.7%	-15,748.4%
Capex / revenue	0.6%	1.0%	5.5%	2,710.6%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 476060

Symbol	Last Price
185750Chong Kun Dang Pharmaceutical Corp.	₩68,000 -0.3%
115180Qurient Co., Ltd.	₩23,050 +17.3%
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.